Active Clinical Trials
Trevi Therapeutics is currently conducting the following clinical trials of the investigational therapy nalbuphine ER. For eligibility criteria and enrollment information, please visit the links below or www.clinicaltrials.gov.
Please note, Nalbuphine ER is an investigational treatment. Its safety and efficacy have not been evaluated by any regulatory authority.
Phase
Trial Name
Length of Treatment
Status
Additional Information
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough
Phase 3
14 Weeks
Not yet recruiting
Refractory Chronic Cough (RCC)
Looking for a completed study? Visit Previous Clinical Trials.
